Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

7.630 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,838
Open 7.630
Bid (Size) 6.950 (200)
Ask (Size) 7.010 (700)
Prev. Close 7.630
Today's Range 7.630 - 7.630
52wk Range 2.250 - 8.795
Shares Outstanding 41,695,335
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
The company is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
News headline image
Compass Pathways Launches Proposed $150.0 Million Public Offering
From Compass Pathfinder Limited
Via Business Wire

Performance

YTD
+16.5%
+16.5%
1 Month
+4.4%
+4.4%
3 Month
+41.6%
+41.6%
6 Month
+86.6%
+86.6%
1 Year
+72.2%
+72.2%

More News

Read More
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Why Did Compass Pathways Stock Rocket Higher Today? ↗
Via The Motley Fool
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
Via Stocktwits
News headline image
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
From Compass Pathfinder Limited
Via Business Wire
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Via Stocktwits
Topics ETFs
News headline image
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Two Investor Conferences in December
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
From Compass Pathfinder Limited
Via Business Wire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Four Investor Conferences in September
From Compass Pathfinder Limited
Via Business Wire

Frequently Asked Questions

Is COMPASS Pathways Plc - American Depository Shares publicly traded?
Yes, COMPASS Pathways Plc - American Depository Shares is publicly traded.
What exchange does COMPASS Pathways Plc - American Depository Shares trade on?
COMPASS Pathways Plc - American Depository Shares trades on the Nasdaq Stock Market
What is the ticker symbol for COMPASS Pathways Plc - American Depository Shares?
The ticker symbol for COMPASS Pathways Plc - American Depository Shares is CMPS on the Nasdaq Stock Market
What is the current price of COMPASS Pathways Plc - American Depository Shares?
The current price of COMPASS Pathways Plc - American Depository Shares is 7.630
When was COMPASS Pathways Plc - American Depository Shares last traded?
The last trade of COMPASS Pathways Plc - American Depository Shares was at 02/17/26 04:00 PM ET
What is the market capitalization of COMPASS Pathways Plc - American Depository Shares?
The market capitalization of COMPASS Pathways Plc - American Depository Shares is 318.14M
How many shares of COMPASS Pathways Plc - American Depository Shares are outstanding?
COMPASS Pathways Plc - American Depository Shares has 318M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.